Novavax Ready to Produce Nearly 3 Billion Coronavirus Vaccine Doses (With a Little Help From Friends)
Novavax (NASDAQ: NVAX) has only completed the first phase of clinical trials for its coronavirus vaccine, NVX-CoV2373, but the relatively small biotech has already lined up at least 2.75 billion in manufacturing capacity through partnerships and an acquisition. Despite not having any drugs on the market, the biotech was able to secure the capacity through about $2 billion in funding from the U.S. government and the Coalition for Epidemic Preparedness Innovations.
Manufacturer
Annual Capacity (Doses)
Source Fool.com
